Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.36 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.35 |
| ▸ | CASP2 | P42575 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 2/20 | 0.32 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1103783 | 0.85 | PAOX (0.52) | KDM4AHIF1ATET2DOHHALDH1A1 | |
| SCHEMBL25863483 | 0.85 | ALDH1A1 (0.39) | ALDH1A1CASP2TSHRGAALMNA | |
| SCHEMBL20224625 | 0.83 | NPC1 (0.36) | ALDH1A1SLC6A5TSHRCYP2C19PAOX | |
| SCHEMBL38654455 | 0.82 | ALDH1A1 (0.42) | KDM4AHIF1ATET2DOHHALDH1A1 | |
| SCHEMBL20794399 | 0.82 | GAA (0.46) | ALDH1A1GAALMNANAAAFAAH | |
| SCHEMBL18588477 | 0.80 | ALDH1A1 (0.39) | ALDH1A1CASP2TSHRGAAKDM4E | |
| SCHEMBL20623023 | 0.78 | ALDH1A1 (0.38) | ALDH1A1CASP2TSHRGAANAAA | |
| SCHEMBL22327482 | 0.78 | SIGMAR1 (0.39) | KDM4AHIF1ATET2DOHHALDH1A1 | |
| SCHEMBL22214508 | 0.77 | CASP2 (0.40) | ALDH1A1CASP2TSHRSMN1; SMN2NAAA | |
| SCHEMBL18588480 | 0.77 | DNM1 (0.54) | ALDH1A1SMN1; SMN2CYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | ASCENDIS PHARMA A/S (DK) | 2023-04-20 | — | — | US | disclosed |
| US-11564974-B2 | Combination therapy with controlled-release CNP agonists | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2023-01-31 | — | — | US | disclosed |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | ASCENDIS PHARMA A/S (DE) | 2023-01-24 | — | — | US | disclosed |
| US-20220409700-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2022-12-29 | — | — | US | disclosed |
| US-20220211817-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2022-07-07 | — | — | US | disclosed |
| US-11311604-B2 | Controlled-release CNP agonists with low NPR-C binding | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-04-26 | — | — | US | disclosed |
| US-20220118053-A1 | Dry Pharmaceutical Formulations of CNP Conjugates | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-04-21 | — | — | US | disclosed |
| US-11224661-B2 | Controlled-release CNP agonists with increased NEP stability | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-20210369848-A1 | Conjugation Method for Carrier-Linked Prodrugs | Ascendls Pharma A/S (DK) | 2021-12-02 | — | — | US | disclosed |
| US-11154593-B2 | CNP prodrugs with large carrier moieties | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2021-10-26 | — | — | US | disclosed |
| US-20190255183-A1 | CNP PRODRUGS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-08-22 | — | — | US | disclosed |
| US-20190022237-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-24 | — | — | US | disclosed |
| US-20190015481-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-17 | — | — | US | disclosed |
| US-20190000926-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-03 | — | — | US | disclosed |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-07-05 | — | — | US | disclosed |
| US-9919033-B2 | Dry growth hormone composition transiently linked to a polymer carrier | ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S (DK) | 2018-03-20 | — | — | US | disclosed |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | ASCENDIS PHARMA A/S (DK) | 2017-04-13 | — | — | US | disclosed |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | ASCENDIS PHARMA GROWTH DISORDERS DIVISION A/S (DK) | 2017-03-02 | — | — | US | disclosed |
| US-8222239-B2 | quaternary ammonium compounds, conjugated to polymers, used as microbiocides | ALLACCEM, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8188068-B2 | Bridged polycyclic compound based compositions for coating oral surfaces in pets | ALLACCEM, INC. (US) | 2012-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409700-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | CNP, NPR1, NTSR2 | KDM4A 3494/4885HIF1A 1835/4885TET2 4378/4885 |
| US-11154593-B2 | CNP prodrugs with large carrier moieties | CNP, LNPEP, CSGALNACT1 | KDM4A 2329/4885HIF1A 2528/4885TET2 2475/4885 |
| US-20190255183-A1 | CNP PRODRUGS | NPPA, NPR1, NPR3 | KDM4A 2361/4885HIF1A 809/4885TET2 2717/4885 |
| US-20210369848-A1 | Conjugation Method for Carrier-Linked Prodrugs | UGT2B7, SLC10A1, UGT1A6 | KDM4A 1331/4885HIF1A 1724/4885TET2 1241/4885 |
| US-20170056477-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | KDM4A 2013/4885HIF1A 563/4885TET2 3461/4885 |
| US-20170100490-A1 | Prodrug Comprising a Drug Linker Conjugate | H1-0, H1-3, H1-2 | KDM4A 750/4885HIF1A 1956/4885TET2 2519/4885 |
| US-20230123784-A1 | Biodegradable Polyethylene Glycol Based Water-Insoluble Hydrogels | PLG, PHYKPL, PLOD3 | KDM4A 618/4885HIF1A 1202/4885TET2 3600/4885 |
| US-20190022237-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY | CNP, NPR1, NPPA | KDM4A 2232/4885HIF1A 1584/4885TET2 4409/4885 |
| US-20190000926-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | NPR1, NPR3, NPSR1 | KDM4A 2493/4885HIF1A 1700/4885TET2 3703/4885 |
| US-20220211817-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | NPR1, NPR3, NPSR1 | KDM4A 2493/4885HIF1A 1700/4885TET2 3703/4885 |
| US-11311604-B2 | Controlled-release CNP agonists with low NPR-C binding | NPR1, NPR3, NPSR1 | KDM4A 2493/4885HIF1A 1700/4885TET2 3703/4885 |
| US-11224661-B2 | Controlled-release CNP agonists with increased NEP stability | CNP, NPR1, NPPA | KDM4A 2232/4885HIF1A 1584/4885TET2 4409/4885 |
| US-20220118053-A1 | Dry Pharmaceutical Formulations of CNP Conjugates | CNP, PTMS, NPPA | KDM4A 4317/4885HIF1A 3355/4885TET2 2978/4885 |
| US-11559482-B2 | Biodegradable polyethylene glycol based water-insoluble hydrogels | PLG, PHYKPL, PLOD3 | KDM4A 618/4885HIF1A 1202/4885TET2 3600/4885 |
| US-11564974-B2 | Combination therapy with controlled-release CNP agonists | CNP, NPR1, NGF | KDM4A 4526/4885HIF1A 928/4885TET2 3927/4885 |
| US-20180185452-A1 | Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier | GHRHR, GHSR, GCG | KDM4A 2013/4885HIF1A 563/4885TET2 3461/4885 |
| US-20190015481-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | CNP, LNPEP, CSGALNACT1 | KDM4A 2329/4885HIF1A 2528/4885TET2 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.